Multi-Strain Probiotic and Postbiotic Formulation for DSS-Induced Colitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory bowel disease (IBD) primarily focus on single-strain probiotics and their metabolites, which are insufficient in effectively mitigating inflammation and regulating gut microbiota, leading to suboptimal clinical outcomes for conditions like colitis.
Innovation Solution
A formulation comprising a mixture of five independently isolated probiotics (Lactobacillus reuteri, Lactobacillus gasseri, Lactobacillus acidophilus, and Bifidobacterium lactis) and their fermentation metabolites, administered in a specific ratio and concentration, to improve gut microbiota composition and reduce inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single-strain probiotics are used, then the formulation is simple and easy to manufacture, but the effectiveness in mitigating inflammation and regulating gut microbiota is insufficient
Solution Approach 1:
The patent combines five different probiotic strains (Lactobacillus reuteri, Lactobacillus gasseri, Lactobacillus acidophilus, and Bifidobacterium lactis) into a single formulation. This merging of multiple strains synergistically enhances the ability to mitigate inflammation and regulate gut microbiota compared to single-strain probiotics, while maintaining manufacturing feasibility through a unified preparation process.
Solution Approach 2:
The patent creates a composite probiotic formulation containing multiple bacterial strains and their metabolites. This composite structure leverages the complementary functions of different strains to achieve superior therapeutic effects in treating inflammatory bowel disease, balancing complexity with enhanced effectiveness.
2Adaptability or versatility
If multi-strain probiotic combinations are used, then the regulation of gut microbiota is improved, but the manufacturing complexity increases
Solution Approach 1:
The patent merges five probiotic strains into a single formulation that can be manufactured using standardized processes. By combining the strains in a defined ratio (1:1:1:1:1), the formulation achieves comprehensive gut microbiota regulation while maintaining ease of manufacture through unified preparation protocols.
Solution Approach 2:
The patent specifies precise parameters for the probiotic formulation, including the ratio of different strains (1:1:1:1:1) and their concentrations. These parameter definitions enable consistent manufacturing and reproduction of the therapeutic effect, making multi-strain formulations as manageable as single-strain products.
3Reliability
If probiotic metabolites are included, then the therapeutic effect is enhanced, but the formulation complexity increases
Solution Approach 1:
The patent combines probiotic strains with their fermentation metabolites into a unified formulation. This merging ensures that both the live bacteria and their functional metabolites work synergistically to enhance therapeutic effects, while the combined formulation can be prepared using a single standardized process rather than separate preparations.
Solution Approach 2:
The probiotic strains produce their own metabolites through fermentation during the formulation preparation process. This self-service mechanism generates the therapeutic metabolites as byproducts of the probiotics' natural metabolism, eliminating the need for separate metabolite production steps and reducing overall formulation complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The probiotic mixture significantly reduces weight loss, histopathological scores, and macrophage infiltration, while enhancing the relative abundance of beneficial bacteria, thereby accelerating intestinal mucosa repair and alleviating DSS-induced colitis.
Implementation Method 1
fermentation metabolites thereof (postbiotics)... Lactobacillus reuteri, Lactobacillus gasseri, Lactobacillus acidophilus, and Bifidobacterium lactis... mixture of five strains... fermentation cultures or the mixture of metabolites
Data Source
AI summary
The invention relates to core components from five strains of independently isolated, identified and patent-deposited probiotics and fermentation metabolites thereof (postbiotics), as well as their use as a protector in alleviating dextran sulfate sodium (DSS) induced-colitis in mice. Further disclosed the mechanism of the probiotics and fermentation metabolites thereof (postbiotics) to alleviate colitis in mice.